Predictive Value of Coronary Calcium Scoring Matthew Budoff, MD, FACC, FAHA Associate Professor of Medicine UCLA School of Medicine Director, Cardiac CT.

Slides:



Advertisements
Similar presentations
2010 ACCF/AHA Guideline for Assessment of Cardiovascular Risk in Asymptomatic Adults Developed in Collaboration with the American Society of Echocardiography,
Advertisements

Summary Prepared by Melvyn Rubenfire, MD
Lipid Management in 2015: Risk & Controversies
Morteza Naghavi, M.D. Society for Heart Attack Prevention and Eradication (SHAPE) Detection and Treatment of Asymptomatic Atherosclerosis for Primary Prevention.
Electron Beam Computed Tomography in the Age of 64 Slice CT Matthew J. Budoff, MD, FACC Associate Professor of Medicine Division of Cardiology Harbor-UCLA.
The Efficacy of Non-invasive Diagnostic for CAD in PMK Hospital Maj. Hutsaya Prasitdumrong, M.D. Cardiovascular Division, Department of Internal Medicine,
New concepts and guidelines in the management of LDL-c and CV Risk: Need for early intervention Prof. Ulf Landmesser University Hospital Zürich Switzerland.
Comparison of the New Mayo Clinic Risk Scores and Clinical SYNTAX Score in Predicting Adverse Cardiovascular Outcomes following Percutaneous Coronary Intervention.
Introduction to: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults BLUF: -Shift from.
TNT: Study Design Treating to New Targets 2 5 years 10,001 Patients Clinically evident CHD LDL-C 130  250 mg/dL following up to 8-week washout and 8-week.
Presenter Disclosure Information Diane Bild, MD, MPH Screening for Subclinical Atherosclerosis as a Strategy for CVD Prevention FINANCIAL DISCLOSURE: None.
Long-term predictive value of assessment of coronary atherosclerosis by contrast- enhanced coronary computed tomography angiography: meta- analysis and.
Morteza Naghavi, M.D. Founder Society for Heart Attack Prevention and Eradication (SHAPE) SHAPE Guidelines Prevention of Fatal Cardiovascular Events (Heart.
Coronary Calcium Scoring for Risk Stratification and Guidelines Matthew Budoff, MD, FACC, FAHA Professor of Medicine Director, Cardiac CT Harbor-UCLA Medical.
Surrogate Measures of Atherosclerosis and Implications for Evaluating Cardiovascular Risk Nathan D. Wong, Ph.D., F.A.C.C. Associate Professor and Director.
Screening and Treatment of Coronary Artery Disease Matthew J. Budoff, MD, FACC Associate Professor of Medicine Division of Cardiology, Harbor-UCLA Medical.
Utility of Biomarkers to Enhance CVD Risk Prediction James de Lemos, MD.
Only You Can Prevent CVD Matthew Johnson, MD. What can we do to prevent CVD?
1 Comparing Zero Coronary Artery Calcium With Other Negative Risk Factors for Coronary Heart Disease A Novel Methodology: Risk-Adjusted Negative Likelihood.
{ A Novel Tool for Cardiovascular Risk Screening in the Ambulatory Setting Guideline-Based CPRS Dialog Adam Simons MD.
Management of Dyslipidemia in Patients with Peripheral Arterial Disease: an update from Guidelines Oman International Vascular Conference Al-Bustan Palace.
HYPERLIPIDAEMIA. 4S 4444 patients –Hx angina or MI –Cholesterol Simvastatin 20mg (10-40) vs. placebo FU 5 years  total cholesterol 25%;  LDL.
COURAGE: Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation Purpose To compare the efficacy of optimal medical therapy (OMT)
Clinical implications. Burden of coronary disease 56 millions deaths worldwide in millions deaths worldwide in % due to CV disease (~ 16.
10 Points to Remember on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in AdultsTreatment of Blood Cholesterol to Reduce.
Should You Be On A Statin Drug?
Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA) Trial MEGA Trial Presented at The American Heart Association.
PPAR  activation Clinical evidence. Evolution of clinical evidence supporting PPAR  activation and beyond Surrogate outcomes studies Large.
Clinical Trial Results. org Long-Term Prognosis Associated with Coronary Calcification Matthew J. Budoff, MD, Leslee J. Shaw, PhD, Sandy T. Liu, Steven.
Secondary Prevention & Cardiac Rehabilitation Malcolm Walker Consultant Cardiologist UCLH & the Heart Hospital, London.
Scandinavian Simvastatin Survival Study (4S) The Lancet, Vol 344, November 19, 1994.
Monitoring CAC and IMT: A useful clinical tool? Cardiology Service Walter Reed Army Medical Center Walter Reed Army Health Care System NO CONFLICTS TO.
Incremental Decrease in Clinical Endpoints Through Aggressive Lipid Lowering (IDEAL) Trial IDEAL Trial Presented at The American Heart Association Scientific.
Studying mortality trends: The IMPACT CHD Policy Model
The Prospective Pravastatin Pooling Project L I P I D CARECARE PPP Project Investigators Am J Cardiol 1995; 76:899–905.
WOSCOPS: West Of Scotland Coronary Prevention Study Purpose To determine whether pravastatin reduces combined incidence of nonfatal MI and death due to.
Ethnic Differences in the Prognostic Value of Coronary Artery Calcification for All-Cause Mortality Khurram Nasir MD MPH, Leslee J. Shaw PhD, Sandy T.
AA-2-1 Jerome D. Cohen, MD, FACC, FACP Professor of Internal Medicine / Cardiology Director, Preventive Cardiology Programs St. Louis University Health.
Clinical Trial Results. org SAGE Trial Prakash Deedwania, MD; Peter H. Stone, MD; C. Noel Bairey Merz, MD; Juan Cosin-Aguilar, MD; Nevres Koylan, MD; Don.
VBWG Predictor of CV Events and Mortality in Postmenopausal Women: Leukocyte Count.
Coronary Artery Calcium
Morteza Naghavi, M.D. Society for Heart Attack Prevention and Eradication (SHAPE) Houston, TX Screening for Early Detection and Prevention of Heart Attack.
The Century Health Trial A Comprehensive Integrated Strategy For Managing CAD K. Lance Gould, M.D. Martin Bucksbaum Distinguished University Chair, Professor.
CARDIAC CT IN SCREENING FOR CAD Hossein Nademi MD CARDIOLOGIST JAVADOL-A-EME HEART HOSPITAL OCT
Unnecessary Lipid Screening of Inpatient Admissions Dennis Whang 4/2/12 DSR2.
Peripheral Artery Disease in Orthopaedic Patients with Asymptomatic Popliteal Artery Calcification on Plain X-ray Adam Podet, MS; Julia Volaufova, phD,;
Are We There Yet ? Abdul H. Sankari, MD FACC FCCP.
○ South Asians (SAs) have high rates of CHD which are not entirely explained by traditional CVD risk factors. ○ The association of a family history of.
CoRPS Center of Research on Psychology in Somatic diseases Brief Depression Screening with the PHQ-2 Predicts Poor Prognosis following PCI with Drug-Eluting.
Matthew P. Ostrom, MD, Ambarish Gopal, MD, Naser Ahmadi, MD, Khurram Nasir, MD, MPH, Eric Yang, MD, Ioannis Kakadiaris, PHD, Ferdinand Flores, BS, Song.
Date of download: 9/18/2016 Copyright © The American College of Cardiology. All rights reserved. From: Implications of Coronary Artery Calcium Testing.
Background/Objective
The role of unknown risk factors in coronary heart disease
CT for Evaluation & Treatment of Cardiovascular Disease
Wm. Guy Weigold, MD, FACC, FSCCT Director of Cardiac CT
Clinical need for determination of vulnerable plaques
Phenotype vs. Genotype: Defining Severe Familial Hypercholesterolemia
Scandinavian Simvastatin Survival Study (4S)
Introduction to: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults BLUF: -Shift from.
Introduction to: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults BLUF: -Shift from.
Neil J. Stone et al. JACC 2014;63:
Introduction to: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults BLUF: -Shift from.
Insights from the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT)
Introduction to: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults BLUF: -Shift from.
Contemporary Evidence-Based Guidelines
Introduction to: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults BLUF: -Shift from.
CT coronary angiography and coronary calcium scoring
Distribution of Cardiovascular Risk Factors by Baseline CRP Concentration M. Cushman et al. Circulation. 2005;112:25-31.
Preventative Cardiology
Requested Information by CMS Team During April 30th Hearing
Presentation transcript:

Predictive Value of Coronary Calcium Scoring Matthew Budoff, MD, FACC, FAHA Associate Professor of Medicine UCLA School of Medicine Director, Cardiac CT Harbor-UCLA Medical Center, Torrance, CA Conflict of Interest: Speakers Bureau General Electric

Prevalence of Conventional Risk Factors in Patients with Coronary Heart Disease (N = 87,869)

Time x A.S. x Coronary atherosclerotic burden – No one is born with atherosclerosis

Time x A.S. x Coronary atherosclerotic burden – There is a gradual, silent build up over time xx x x x x x x x

Time x A.S. x Coronary atherosclerotic burden – Finally, acute event occurs xx x x x x x x x x x

Time x A.S. x Coronary atherosclerotic burden – Sx onset -- Permanent damage xx x x x x x x x x x Time 1 1/3 - Angina 1/3 - Acute MI 1/3 - Sudden Death

Time x A.S. x Coronary atherosclerotic burden – xx x x x x x x x x x 1 st Event Realistic Goal – DELAY PROGRESSION x x x x x xxxxxxx x x x x x x x x x x x x x x x

Time x A.S. x Coronary atherosclerotic burden – xx x x x x x x x x x 1 st Event Prevention- Primary vs. Secondary x x x x x xxxxxxx x x x x x x x x x x x x x x x CARDIOLOGISTS

Time x A.S. x Coronary atherosclerotic burden – xx x x x x x x x x x 1 st Event Prevention- Primary vs. Secondary x x x x x xxxxxxx x x x x x x x x x x x x x x x PRIMARY CARE

Time x A.S. x Coronary atherosclerotic burden – xx x x x x x x x x x 1 st Event Concept -- EARLY 2 ry PREVENTION x x x x x xxxxxxx x x x x x x x x x x x x x x x The Problem begins HERE NOT HERE

Potential Prognostic Potential of Cardiac CT l Use a calcium score to screen patients with moderate (intermediate) Framingham risk n Positive CAC scans indicate incremental risk n Alters therapeutic goal (LDL, BP, etc) l Identify patients who do not need further cardiac medication (scores of zero) l Consider serial imaging as ongoing management tool (progression)

Prediction of Cardiac Events in Asymptomatic Patients by EBT The St. Francis Heart Study, ACC 2003 SFHS 3 Baseline EBT Calcium Score Annual Event Rate (%) Calcium Score >100 vs <100 Relative Risk 9.5 Any Event 10.7 Cor. Event 9.9 MI/ SCD

Relative Risk DMSmokeHTN< >1000 EBT Coronary Calcium Score All Cause Mortality [NDR] n = 10,377 asymptomatic men and women f/u = yrs. Shaw, Raggi et al Radiology 2003 EBT found to be independent and incremental to risk factors All Cause Mortality in Patients Without Known CAD

EBT 5 year All-Cause Mortality – Shaw et al

Time to Follow-up (Years) Time to Follow-up (Years) Near- and Long-Term Survival from 2 Cohorts – over 35,000 patients n=10,377 n=25, % 97.8% 95.2% 90.4% 81.8% 99.4% 97.8% 94.5% 93.0% 76.9%  2 =1503, p<0.0001, interaction p<o.0001 CAC Score (5 Yr Mortality = 1.2%) (12-Yr Mortality = 2.1%)Difference % 99.4% 0.0% % 97.8% 0.0% % 94.5% 0.7% 401-1, % 93.0% 0.6% >1, % 76.9% 4.9%

Cooper Clinic Study - 10,782 Patients: 3.5 year follow-up Adjusted age, history of diabetes, hypertension, elevated cholesterol, over weight 44.3 (22-87) 2.9 ( ) 5.2 (2.4-11) 13.4 ( ) Ref All CHD (n=278) Nonfatal MI & CHD Death 2.7 ( ) 6.0 (2.1-17) 9.7 (3.6-26) 21.1 (7.8-57) Ref

Taylor et al – PACC Study – JACC 2005 l 2000 patients, mean age 43 l Coronary calcium was associated with an 11.8-fold increased risk for incident coronary heart disease (CHD) (p 0.002) in a Cox model controlling for the Framingham risk score. l In young, asymptomatic men, the presence of coronary artery calcification provides substantial, cost-effective, independent prognostic value in predicting incident CHD that is incremental to measured coronary risk factors.

Calcium Versus Framingham

RR of MI/SCD: EBT Score and hs-CRP Low hs-CRP High hs-CRP Park et al. Circ. 2002;

AHA – Circulation 2005 Given the evolving literature since the last ACC/AHA Expert Consensus statement (2000), current data indicate that CAD risk stratification is possible with CAC measures. Specifically, low CAC scores are associated with a low adverse event risk, and high CAC scores are associated with a worse event-free survival. This recommendation to measure atherosclerosis burden, in clinically selected intermediate–CAD risk patients (eg, those with a 10% to 20% Framingham 10- year risk estimate) to refine clinical risk prediction and to select patients for altered targets for lipid-lowering therapies.

RAGGI - ATVB

Arad et al. JACC 2005 l In the largest study reported to date, multiple logistic regression, demonstrated only age (p 0.03), male gender (p 0.04), LDL cholesterol (p 0.01), HDL cholesterol (p 0.04), and two-year change in calcium score (p ) were significantly associated with subsequent CAD events. l Thus, increasing calcium scores were most strongly related to coronary events. l NOT PREDICTIVE: Baseline CAC, CRP

Potential Uses of Cardiac CT l Use a calcium score to screen patients with moderate (intermediate) Framingham risk n Positive EBT scans indicate incremental risk n Alters therapeutic goal (LDL, BP, etc) l Identify patients who do not need further cardiac evaluation (scores of zero) l Consider serial imaging as ongoing management tool (progression) l Improve compliance l Non-invasive Angiography

Percentage of individuals maintaining Statin therapy at 3.6 years according to various levels of baseline CAC

EBT Coronary Calcium